---
title: "Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295802065.md"
description: "Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on Scholar Rock Holding (SRRK) with a $62 price target, while shares closed at $53.82. The broader analyst consensus remains a Strong Buy with an average target of $62.10, implying 15.38% upside. Additionally, J.P. Morgan maintained its Buy rating with a $63 target."
datetime: "2026-08-13T12:45:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295802065.md)
  - [en](https://longbridge.com/en/news/295802065.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295802065.md)
---

# Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on Scholar Rock Holding yesterday and set a price target of $62.00. The company’s shares closed yesterday at $53.82.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Nachman is a 2-star analyst with an average return of 0.5% and a 46.31% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Achieve Life Sciences.

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $62.10, implying a 15.38% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a $63.00 price target.

### Related Stocks

- [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [ACHV.US](https://longbridge.com/en/quote/ACHV.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA](https://longbridge.com/en/news/295354098.md)
- [Scholar Rock Readies for Apitegromab Launch Amid Risks](https://longbridge.com/en/news/295726510.md)
- [Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates](https://longbridge.com/en/news/295175378.md)
- [Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule](https://longbridge.com/en/news/295429730.md)
- [UBS Reaffirms Their Buy Rating on Ottobock SE & Co. KGaA (OBCKF)](https://longbridge.com/en/news/295776943.md)